Key facts
- This page summarizes Max Rosett's Form 4 filing for Immunome Inc. (IMNM).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 Sep 2024, 19:26.
Max Rosett - 19 Sep 2024 Form 4 Insider Report for Immunome Inc. (IMNM)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- IMNM
- Reported as of
- 19 Sep 2024
- Net transaction value
- -$186,124
- SEC form
- 4
- Accepted by SEC
- 20 Sep 2024, 19:26:16 UTC
- Prior SEC filing
- 13 Aug 2024
- Next SEC filing
- 31 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sandra Stoneman, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Max Rosett filed Form 4 for Immunome Inc. (IMNM) on 20 Sep 2024.
Change
- Previous filing in this sequence was filed on 13 Aug 2024.
- Current net transaction value: -$186,124.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMNM
transaction
Common Stock
Options Exercise
- Transaction value
- $44,100
- Shares
- +42,000
- Change %
- +212%
- Price
- $1.05
- Shares after
- 61,856
- Date
- 19 Sep 2024
- Ownership
- Direct
IMNM
transaction
Common Stock
Sale
- Transaction value
- $230,224
- Shares
- -14,380
- Change %
- -23%
- Price
- $16.01
- Shares after
- 47,476
- Date
- 19 Sep 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMNM
transaction
Derivative
Stock option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -42,000
- Change %
- -31%
- Price
- $0.000000
- Shares after
- 91,848
- Date
- 19 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 42,000
- Exercise price
- $1.05
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The shares were sold pursuant to sell to cover transactions.
Footnote F2
The weighted average sale price for the transaction report was $16.01, and the range of prices were between $15.97 and $16.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
Footnote F3
The Reporting Person's Form 3 filed on October 12, 2023 contains a scrivener's error reflecting an exercise price of $1.06 instead of the correct exercise price of $1.05.
Footnote F4
25% of the shares vested on March 24, 2023, and the remaining shares shall vest in 36 monthly installments thereafter.